Bridge Therapeutics
Manufacturing · Alabama, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
217 Country Club Park Pmb 325, Birmingha...Phone Number
(877) 223-6949Website
www.bridgetherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Bridge Therapeutics
Bridge Therapeutics is a development-stage pharmaceutical company focused on obtaining FDA approval for its innovative drug therapies. The company is working on BT-219, a superior delivery system of buprenorphine-naloxone aimed at treating opioid use disorder (OUD), and BT-205, a patented drug combination designed for chronic pain management in patients with a history of opioid use. Their mission is to enhance healthcare outcomes for patients suffering from OUD and chronic pain through safer and more effective treatment options. Intended clients include patients with opioid use disorder and those experiencing chronic pain who are seeking alternatives to standard opioid therapies.Explore more
Bridge Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bridge Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Bridge Therapeutics launches new products
Click to see if Bridge Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Bridge Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Bridge Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Bridge Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Bridge Therapeutics
Funding: Get notified immidiatlly once Bridge Therapeutics has new funding data
Check out if Bridge Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Bridge Therapeutics
Find more new buyers
Compare Similar Companies to Bridge Therapeutics
Compare insights from companies similar to Bridge Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bridge Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bridge Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bridge Therapeutics.
Bridge Therapeutics Tech Stack
A closer look at the technologies used by Bridge Therapeutics
See more technologies
Bridge Therapeutics News & Media
Bridge Therapeutics Announces It Will Seek FDA Approval for BT-219, a Treatment for Opioid Dependence in the Coming Months
Bridge Therapeutics Inc. today announced that it has received feedback from the Food and Drug Administration (FDA) from a Pre-Investigational Ne ...Bridge Therapeutics Announces the Addition of Edward J. Minskoff to Its Board of Directors
BIRMINGHAM, Ala., April 23, 2019 /PRNewswire/ -- Bridge Therapeutics, an innovative startup pharmaceutical company developing a practical and safe therapy for chronic pain, is pleased to announce the addition of Edward J. Minskoff to its board of directors. As a major Manhattan real...Dr. Steven Passik Has Joined the Scientific Advisory Board of Bridge Therapeutics
BIRMINGHAM, Ala., Nov. 7, 2018 /PRNewswire/ -- Steve Passik Ph.D., Clinical Psychology, is a recognized leader and researcher in pain management and addiction. The intersection of pain and addiction has been the focus for much of his teaching activities and peer reviewed articles. He has...Bridge Therapeutics Announces the Addition of Dr. Bob Rappaport to Its Scientific Advisory Board
BIRMINGHAM, Ala., Nov. 2, 2018 /PRNewswire/ -- Dr. Bob Rappaport, MD, has worked on advancing anesthesia, analgesia, and addiction drug-treatment research, discovery, and evaluation, in the private sector through his consulting firm Analgesic Concepts LLC. Dr. Rappaport also has an...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bridge Therapeutics
Sign Up For FreeTo access detailed company insights
Bridge Therapeutics is a development-stage pharmaceutical company focused on obtaining FDA approval for its innovative drug therapies. The company is working on BT-219, a superior delivery system of buprenorphine-naloxone aimed at treating opioid use disorder (OUD), and BT-205, a patented drug combination designed for chronic pain management in pat... Read More
